Does prolonged use of diphenylhydantoin predispose to pulmonary sarcoidosis?
We describe 3 patients with epilepsy who developed sarcoidosis, stage I, while being treated with diphenylhydantoin for prolonged periods. We are unaware of such an association in the literature. However, in the light of the current knowledge about the adverse immunologic reactions that may be caused by diphenylhydantoin and the altered immunological state described in sarcoidosis, we recommend physicians to look for and report on similar cases in order to assess possible cause and effect relationships between the two.
D000328:Adult; D004827:Epilepsy / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D008171:Lung Diseases / Q000209:etiology* / Q000276:immunology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000145:classification; D008297:Male; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects*; D012507:Sarcoidosis / Q000209:etiology* / Q000276:immunology; D013997:Time Factors
D007136:Immunoglobulins; D010672:Phenytoin